Catabasis Pharmaceuticals

Overview

Compare with DiaMedica Therapeutics Inc., EXICURE, INC. or Imunon, Inc., or pick any stock.

• TickerCATB on NASDAQ¹
• IndustryPharmaceutical Preparations¹
• HeadquartersCambridge¹
• Websitewww.catabasis.com
• Incorporated inDE³
• Business address22 Boston Wharf Road, 10Th Floor, Boston, Ma 02210³
• Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Our focus is to develop first-choice therapies that improve the health and outcomes of patients with allergic and immunologic diseases. Our lead product candidate is navenibart, formerly known as STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. We believe that navenibart has the potential to be the market - leading and most patient-friendly chronic treatment option for HAE, based on proof-of-concept data in HAE patients and the existing HAE treatment landscape. Our second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinic…⁵ From its latest annual report

Corporate structure

Catabasis Pharmaceuticals sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Catabasis Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Real estate and locations

Investments

Properties, in its own words

Our offices are located in Boston, Massachusetts and consist of approximately 30,110 square feet of subleased office space under a lease that is scheduled to end on November 30, 2028 or on such earlier date as the term may sooner cease or expire as set forth in the sublease agreement. We believe that our existing facilities are sufficient for our needs for the foreseeable future.

Item 2 of the 10-K filed Mar 11, 2025.⁵

Leadership

Who has led Catabasis Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJill C. Milne Jun 24, 2015 to now¹⁴
• PresidentJill C. Milne Jun 24, 2015 to now¹⁴
• Chief financial officerNoah Clauser Sep 21, 2020 to now¹⁵
• Chief financial officerIan C. Sanderson Jun 24, 2015 to Feb 16, 2016¹⁶

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• Astria Securities Corporation Delaware⁴
• Quellis Biosciences, LLC Delaware⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• CATABASIS PHARMACEUTICALS INCJan 21, 2009 to Aug 20, 2021³

Timeline

1. Jan 23, 20268-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation⁴¹
2. Jan 21, 20268-K Shareholder vote; Other events⁴²
3. Dec 23, 20258-K Other events⁴³
4. Nov 12, 20258-K Results of operations⁴⁴
5. Oct 14, 20258-K Entered a material agreement; Results of operations; Other events⁴⁵
6. Aug 6, 20258-K Entered a material agreement; Regulation FD disclosure; Other events⁴⁶
7. Jun 12, 20258-K Executive or director change; Shareholder vote⁴⁷
8. Mar 11, 20258-K Results of operations⁴⁸
9. Jan 13, 20258-K Regulation FD disclosure⁴⁹
10. Dec 19, 20248-K Executive or director change⁵⁰
11. Jun 6, 20248-K Executive or director change; Shareholder vote⁵¹
12. Apr 9, 20248-K Executive or director change⁵²
13. Jun 24, 2015New chief executive Jill C. Milne becomes CEO¹⁴
14. 2008Founded Founded¹

Calendar

When it reported results

1. Nov 12, 2025Reported quarterly or annual results⁴⁴
2. Oct 14, 2025Reported quarterly or annual results⁴⁵
3. Mar 11, 2025Reported quarterly or annual results⁴⁸
4. Nov 13, 2023Reported quarterly or annual results⁵³
5. Mar 22, 2023Reported quarterly or annual results⁵⁴
6. Jan 5, 2023Reported quarterly or annual results⁵⁵
7. Nov 10, 2021Reported quarterly or annual results⁵⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

279 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 36 major events, 87 insider forms, 67 large holders, 72 other. The latest 20:

1. Feb 17, 2026SCHEDULE 13G/A EDGAR
2. Feb 12, 2026SCHEDULE 13G/A EDGAR
3. Feb 9, 2026SCHEDULE 13D/A EDGAR
4. Feb 2, 202615-12G EDGAR
5. Jan 28, 2026SCHEDULE 13D/A EDGAR
6. Jan 27, 2026EFFECT EDGAR
7. Jan 27, 2026EFFECT EDGAR
8. Jan 27, 2026EFFECT EDGAR
9. Jan 27, 2026EFFECT EDGAR
10. Jan 27, 2026EFFECT EDGAR
11. Jan 27, 2026EFFECT EDGAR
12. Jan 23, 2026S-8 POS EDGAR
13. Jan 23, 2026S-8 POS EDGAR
14. Jan 23, 2026S-8 POS EDGAR
15. Jan 23, 2026S-8 POS EDGAR
16. Jan 23, 2026S-8 POS EDGAR
17. Jan 23, 2026S-8 POS EDGAR
18. Jan 23, 2026S-8 POS EDGAR
19. Jan 23, 2026S-8 POS EDGAR
20. Jan 23, 2026S-8 POS EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 5 buys and 3 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Vestal Point Capital, LPSCHEDULE 13G/A, 3 filings Nov 14, 2024 to Feb 17, 2026⁵⁷
• GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings Dec 10, 2025 to Feb 12, 2026⁵⁸
• PERCEPTIVE ADVISORS LLCSCHEDULE 13D/A, 6 filings Dec 21, 2022 to Feb 9, 2026⁵⁹
• Magnetar Financial LLCSCHEDULE 13D/A, 2 filings Oct 24, 2025 to Jan 28, 2026⁶⁰
• Pa B.v. Forgrowth Iii.SCHEDULE 13G/A, 3 filings Jan 7, 2025 to Nov 14, 2025⁶¹
• FMR LLCSCHEDULE 13G/A, 9 filings Jan 10, 2023 to Nov 7, 2025⁶²
• INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 4 filings Nov 1, 2024 to Oct 20, 2025⁶³
• Fairmount Funds Management LLCSCHEDULE 13G/A, 6 filings Feb 8, 2022 to Oct 15, 2025⁶⁴
• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 5 filings Feb 14, 2022 to Aug 14, 2025⁶⁵
• Venrock Healthcare Capital Partners III, L.P.SCHEDULE 13G/A, 3 filings Jan 2, 2024 to Feb 14, 2025⁶⁶
• TCG Crossover GP II, LLCSC 13G/A, 2 filings Jan 16, 2024 to Nov 13, 2024⁶⁷
• VANGUARD GROUP INCSC 13G/A, 5 filings Feb 13, 2024 to Nov 12, 2024⁶⁸
• BlackRockSC 13G, 5 filings Feb 24, 2022 to Nov 8, 2024⁶⁹
• Cormorant Asset Management, LPSC 13G/A, 3 filings Sep 2, 2022 to Feb 14, 2024⁷⁰
• Deep Track Capital, LPSC 13G/A, 3 filings Dec 22, 2022 to Feb 14, 2024⁷¹
• Vivo Opportunity, LLCSC 13G/A, 3 filings Sep 8, 2022 to Feb 13, 2024⁷²
• Altium Capital Management LLCSC 13G/A, 2 filings Dec 21, 2022 to Feb 14, 2023⁷³
• Rosalind Advisors, Inc.SC 13G, 1 filing Jan 7, 2022⁷⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How Catabasis Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARAstria Therapeutics, Inc.²
• CIK0001454789
• Employer ID (EIN)26-3687168⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31²
• Industry code (SIC)2834 Pharmaceutical Preparations²
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance²
• Business address22 Boston Wharf Road, 10Th Floor, Boston, MA 02210²
• Phone617-349-1971²
• Shares outstanding57,084,838 as of Oct 31, 2025¹¹
• Public float$370.2M as of Jun 28, 2024⁵
• AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceJan 21, 2009²
• Filings628 in all: 4 (171), 8-K (83), SC 13G/A (45), 10-Q (32), 3 (31), SC 13G (30), 424B5 (21), EFFECT (15)²
  All 50 form types

  SCHEDULE 13G/A (15), CORRESP (13), 4/A (12), DEF 14A (12), S-8 (12), S-8 POS (12), DEFA14A (11), SC 13D/A (11), 10-K (10), 425 (8), POS AM (7), UPLOAD (7), 424B3 (6), D (6), S-3 (6), S-1/A (5), D/A (4), PRE 14A (4), S-3/A (4), SC 13D (4), ARS (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), 144 (2), 424B4 (2), S-1 (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 25-NSE/A (1), 5 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), REGDEX (1), S-1MEF (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Mar 11, 2025
  Quarterly report (10-Q) Nov 12, 2025
  Proxy statement (DEF 14A) Apr 28, 2025
  Latest 8-K (8-K) Jan 23, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 11, 2025 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks Catabasis Pharmaceuticals names in Item 1A of its 10-K filed Mar 11, 2025: 71 risks under these headings, as written.⁵

• Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
• Our business is entirely dependent on the success of navenibart as a potential treatment for HAE and STAR-0310 as a potential treatment for AD.
• Interim topline, initial proof-of-concept and preliminary data from our clinical trials that we announce or publish from time to time may change as more study participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, and results of later stage clinical trials may not enable marketing approval.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome. If clinical trials of a product candidate fail to satisfactorily demonstrate safety and efficacy to the FDA and other comparable foreign regulators, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.
• Adverse events or undesirable side effects caused by, or other unexpected properties of, a product candidate may be identified during development that could delay or prevent their marketing approval or limit their use.
• If we, or any future collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of a product candidate, potential marketing approval or commercialization of such product candidate could be delayed or prevented.
• If we, or any future collaborators, experience delays or difficulties in the enrollment of patients in clinical trials, our or their receipt of necessary regulatory approvals could be delayed or prevented.
• We have conducted and intend to conduct certain of our clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business.
• Changes in product candidate manufacturing or formulation may result in additional costs or delay.
• We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively.
• We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Legal proceedings

From time to time we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.⁵

Links

• Websitewww.catabasis.com¹
• WikidataQ17143508
• SEC EDGARCIK 1454789